Pharma
Indian Drugmakers Prepare to Launch Generic Semaglutide as Ozempic Patent Expires
Patent expiry of semaglutide in March 2026 is set to enable Indian drugmakers to launch generics, expanding access to diabetes and obesity treatments
India’s pharmaceutical sector is gearing up for a major shift in the diabetes and obesity treatment market as the patent for Semaglutide—the active ingredient in blockbuster drugs Ozempic and Wegovy—is set to expire in the country on March 20, 2026. The expiry will allow domestic manufacturers to launch generic versions, potentially expanding access to these therapies for millions of patients.
Several Indian pharmaceutical companies, including Sun Pharmaceutical Industries, Zydus Lifesciences, Lupin Limited, MSN Laboratories, Alkem Laboratories, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Natco Pharma are reportedly preparing to introduce their own semaglutide formulations soon after the patent lapses. The original drugs were developed by Novo Nordisk, which has dominated the global GLP-1 market with Ozempic for type 2 diabetes and Wegovy for weight management.
With the patent expiry approaching, several companies are expected to move quickly with product launches in the weeks following March 20, 2026, marking the entry of multiple generic versions into the Indian market. The presence of several manufacturers is likely to increase competition and accelerate the adoption of GLP-1–based therapies in the country.
Semaglutide belongs to the class of GLP-1 receptor agonists, a group of drugs that mimic the hormone glucagon-like peptide-1 to help regulate blood glucose levels, slow gastric emptying, and promote satiety. Because of these effects, GLP-1–based therapies have gained increasing attention not only for glycaemic control in type 2 diabetes but also for their benefits in weight management and cardiometabolic risk reduction.
Recent international diabetes guidelines, including those from the American Diabetes Association and the European Association for the Study of Diabetes, increasingly recommend GLP-1 receptor agonists as important treatment options for patients with type 2 diabetes, particularly those with obesity or cardiovascular risk. These recommendations have contributed to the rapid global uptake of GLP-1 therapies.
The patent expiry is expected to trigger the launch of numerous branded generic versions in India, making semaglutide more widely available. This development could reshape the country’s diabetes and obesity therapeutics market, which is projected to grow rapidly in the coming years.
While the broader availability of semaglutide may improve treatment access, healthcare experts also emphasize that these medications should be used under proper medical supervision, as they are intended for specific clinical indications and require careful patient selection and monitoring.
Note: Medications mentioned in this article should be used only under medical supervision.
Several Indian pharmaceutical companies, including Sun Pharmaceutical Industries, Zydus Lifesciences, Lupin Limited, MSN Laboratories, Alkem Laboratories, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Natco Pharma are reportedly preparing to introduce their own semaglutide formulations soon after the patent lapses. The original drugs were developed by Novo Nordisk, which has dominated the global GLP-1 market with Ozempic for type 2 diabetes and Wegovy for weight management.
With the patent expiry approaching, several companies are expected to move quickly with product launches in the weeks following March 20, 2026, marking the entry of multiple generic versions into the Indian market. The presence of several manufacturers is likely to increase competition and accelerate the adoption of GLP-1–based therapies in the country.
Semaglutide belongs to the class of GLP-1 receptor agonists, a group of drugs that mimic the hormone glucagon-like peptide-1 to help regulate blood glucose levels, slow gastric emptying, and promote satiety. Because of these effects, GLP-1–based therapies have gained increasing attention not only for glycaemic control in type 2 diabetes but also for their benefits in weight management and cardiometabolic risk reduction.
Recent international diabetes guidelines, including those from the American Diabetes Association and the European Association for the Study of Diabetes, increasingly recommend GLP-1 receptor agonists as important treatment options for patients with type 2 diabetes, particularly those with obesity or cardiovascular risk. These recommendations have contributed to the rapid global uptake of GLP-1 therapies.
The patent expiry is expected to trigger the launch of numerous branded generic versions in India, making semaglutide more widely available. This development could reshape the country’s diabetes and obesity therapeutics market, which is projected to grow rapidly in the coming years.
While the broader availability of semaglutide may improve treatment access, healthcare experts also emphasize that these medications should be used under proper medical supervision, as they are intended for specific clinical indications and require careful patient selection and monitoring.
Note: Medications mentioned in this article should be used only under medical supervision.
Diabetes TreatmentsGeneric Drugs IndiaGLP-1 Therapies
